{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:08:15Z","timestamp":1773965295537,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clinthera.2025.12.009","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:55:23Z","timestamp":1767876923000},"page":"186-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Equivalence of AmphosomTM, a Newly Developed Liposomal Amphotericin B, to Ambisome\u24c7"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-5120","authenticated-orcid":false,"given":"Seunghoon","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Seok","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungpil","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Yeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raeseok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dukhee","family":"Nho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Jeong","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.12.009_bib0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0002","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.clinthera.2021.09.011","article-title":"Amphotericin-associated infusion-related reactions: a narrative review of pre-medications","volume":"43","author":"Scardina","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0003","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function","author":"Aguirre","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2025.12.009_bib0005","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","article-title":"Liposomal amphotericin B\u2014the present","volume":"77","author":"Maertens","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2025.12.009_bib0006","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0007","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jac\/dkac389","article-title":"Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis","volume":"78","author":"Stott","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0008","doi-asserted-by":"crossref","first-page":"e01477","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1208\/s12248-017-0049-9","article-title":"Liposomal drug product development and quality: current US experience and perspective","volume":"19","author":"Kapoor","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2020.09.008","article-title":"Analytical method development and comparability study for AmBisome and generic amphotericin B liposomal products","volume":"157","author":"Liu","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0011","first-page":"275","article-title":"Liposomal formulations of amphotericin B: differences according to the scientific evidence","volume":"28","author":"Reis","year":"2015","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpddr.2018.04.001","article-title":"Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome and AmBisome in murine cutaneous leishmaniasis","volume":"8","author":"Wijnant","year":"2018","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0014","unstructured":"US Food and Drug Administration. Draft guidance on amphotericin B. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_050740.pdf."},{"key":"10.1016\/j.clinthera.2025.12.009_bib0015","unstructured":"European Medicines Agency. Liposomal amphotericin B powder for dispersion for infusion 50 mg product-specific bioequivalence guidance. 2021. https:\/\/https:\/\/www.ema.europa.eu\/en\/liposomal-amphotericin-b-product-specific-bioequivalence-guidance."},{"key":"10.1016\/j.clinthera.2025.12.009_bib0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jchromb.2009.11.036","article-title":"Vaidya VV. Determination of free and liposomal amphotericin B in human plasma by liquid chromatography\u2013mass spectroscopy with solid phase extraction and protein precipitation techniques","volume":"878","author":"Deshpande","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0017","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1128\/AAC.01427-16","article-title":"Population pharmacokinetics of liposomal amphotericin B in immunocompromised children","volume":"60","author":"Lestner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0018","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0019","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00933-12","article-title":"Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0020","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.3389\/fimmu.2019.02978","article-title":"Effects of antirejection drugs on innate immune cells after kidney transplantation","volume":"10","author":"Zaza","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2025.12.009_bib0021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","article-title":"Amphotericin B pharmacokinetics in humans","volume":"13","author":"Atkinson","year":"1978","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:55:44Z","timestamp":1773957344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825004199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0149291825004199"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic Equivalence of AmphosomTM, a Newly Developed Liposomal Amphotericin B, to Ambisome\u24c7","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}